Comparison of clinical and immunological effects of intravenous and intradermal administration of α-GalactosylCeramide (KRN7000)-pulsed dendritic cells

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 5140-5151

  Nicol, Andrew J ^a   Tazbirkova, Andrea ^a   Nieda, Mie ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; GAMMA INTERFERON;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; KIDNEY CARCINOMA; LETHARGY; LIVER CANCER; LUNG CARCINOMA; LYMPHOCYTE ACTIVATION; MALAISE; MALE; MELANOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PERITONEAL ADENOCARCINOMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PULSED DENDRITIC CELL; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; AGED; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAVENOUS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 79960986584     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3105     Document Type: Article

References (38)

1. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8. (Pubitemid 26028073)
2. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80. (Pubitemid 27014352)
3. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumour lysatepulsed dendritic cells. Nat Med 1998;4:328-32. (Pubitemid 28144092)
4. Rees RC, Mian S. Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol Immunother 1999;48:374-81. (Pubitemid 29461390)
5. Bubeník J. MHC class I down-regulation: tumour escape from immune surveillance? Int J Oncol 2004;25:487-91.
6. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
7. Kikuchi A, Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, et al. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Br J Cancer 2001;85:741-6. (Pubitemid 32929474)
8. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, et al. TRAIL expression by activated human CD4(+)V alpha 24+NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001;97:2067-74. (Pubitemid 32239088)
9. Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, et al. Human invariant Valpha24+ natural killer T cells activated by alphagalactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 2000;99:229-34. (Pubitemid 30093668)
10. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, et al. Sequential production of interferon-gamma by NK1.1(±) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002;99:1259-66. (Pubitemid 34547079)
11. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, et al. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alphagalactosylceramide. Eur J Immunol 2001;31:1720-7. (Pubitemid 32547334)
12. Nakagawa R, Motoki K, Ueno H, Iijima R, Nakamura H, Kobayashi E, et al. Treatment of hepatic metastasis of the colon26 adenocarcinom a with an alpha-galactosylceramide, KRN7000. Cancer Res 1998;58:1202-7. (Pubitemid 28183209)
13. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumour metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999;163:2387-91. (Pubitemid 29399156)
14. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, et al. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res 1999;59:5102-5. (Pubitemid 29503967)
15. Takahashi T, Nieda M, Koezuka Y, Nicol A, Porcelli SA, Ishikawa Y, et al. Analysis of human Vα24+ NKT cells activated by α-glycolsylceramide- pulsed monocyte derived dendritic cells. J Immunol 2000;164:4458-64. (Pubitemid 30238040)
16. Lickliter JD, Cox J, McCarron J, Martinez NR, Schmidt CW, Lin H, et al. Small-molecule Bcl-2 inhibitors sensitize tumour cells to immunemediated destruction. Br J Cancer 2007;96:600-8.
17. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A Phase I study of the natural killer T-cell ligand alpha-Galactosylceramide (KRN7000) in patients with solid tumours. Clin Cancer Res2002;8:3702-9. (Pubitemid 35424759)
18. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFNgamma - producing NKT response induced with alpha-galactosylceramide - loaded DCs. Nat Immunol 2002;3:867-74.
19. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of V{alpha}24+V{beta}11+NKT cells in human subjects results in highly co-ordinated secondary activation of acquired and innate immunity. Blood 2004;103:383-9. (Pubitemid 38140063)
20. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005;201:1503-17. (Pubitemid 40664093)
21. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, et al. Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Canc Immunol Immunother2008;57:337-45. (Pubitemid 350295376)
22. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GMCSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009;182:2492-501.
23. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, et al. A phase I study of in vitro expanded natural killer T cells inpatients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006;12:6079-86. (Pubitemid 44703772)
24. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-galactosyl ceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministration protein. J Exp Med 2003;198:267-79. (Pubitemid 36987852)
25. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-8. (Pubitemid 29062955)
26. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002;100:1354-61. (Pubitemid 34864292)
27. Sallusto F, Palermo B, Lenig D, Miettinen M, Matikainen S, Julkunen I, et al. Distinct patterns and kinetics of chemokine production regulatedendritic cell function. Eur J Immunol 1999;29:1617-25. (Pubitemid 29224467)
28. Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, et al. Preserved IFN-alpha production of circulating Vα24NKTcells in primary lung cancer patients. Int J Cancer 2002;102:159-65. (Pubitemid 35168029)
29. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001;166:4254-9. (Pubitemid 32224961)
30. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cell for tumor immunotherapy. Proc Natl Acad Sci 2001;98:8809-14. (Pubitemid 32678109)
31. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26. (Pubitemid 34533020)
32. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, et al. NKTcells enhance CD4+ and CD8+ T cell responses to soluble antigen invivo through direct interaction with dendritic cells. J Immunol 2003;171:5140-7. (Pubitemid 37432797)
33. Stober D, Jomantaite I, Schirmbeck R, Reimann J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol 2003;170:2540-8. (Pubitemid 36245644)
34. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in Tcell-mediated immunotherapy. J Clin Invest 2004;114:1800-11. (Pubitemid 40385536)
35. Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, Mordoh J, et al. Innate NKT lymphocytes confer superior adaptive immunity viatumour-capturing dendritic cells. J Exp Med 2005;202:1507-16. (Pubitemid 41746597)
36. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Crosspresentationof glycolipid from tumour cells loaded with alpha-galactosylceramideleads to potent and long-lived T cell mediated immunityvia dendritic cells. J Exp Med 2007;204:2641-53. (Pubitemid 350063944)
37. Taraban VY, Martin S, Attfield KE, Glennie MJ, Elliott T, Elewaut D, et al. Invariant NKT cells promote CD8+ cytotoxic T cell responses byinducing CD70 expression on dendritic cells. J Immunol 2008;180:4615-20.
38. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loadedwith alpha- galactosylceramide induce innate NKT and NK cell-dependentresistance to tumor implantation in mice. J Immunol 2007;178:2853-61. (Pubitemid 46333163)